Clive Brown - Oxford Nanopore CTO Director
| ONTTF Stock | USD 1.96 0.08 3.92% |
Insider
Clive Brown is CTO Director of Oxford Nanopore Technologies
| Phone | 44 84 5034 7900 |
| Web | https://nanoporetech.com |
Oxford Nanopore Management Efficiency
The company has return on total asset (ROA) of (0.1396) % which means that it has lost $0.1396 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2843) %, meaning that it generated substantial loss on money invested by shareholders. Oxford Nanopore's management efficiency ratios could be used to measure how well Oxford Nanopore manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Min | Genscript Biotech | N/A | |
| Yanju Wang | Innovent Biologics | 34 | |
| Changshou Gao | Innovent Biologics | N/A | |
| ACIS ACS | Genscript Biotech | 42 | |
| John CPA | MediciNova | N/A | |
| Blake Salisbury | Innovent Biologics | N/A | |
| Scott Thomas | Seer Inc | 51 | |
| Michael Rap | Nurix Therapeutics | N/A | |
| Hing Wong | HCW Biologics | 70 | |
| Min Liu | Innovent Biologics | N/A | |
| Darlene Noci | Nuvalent | 46 | |
| Serafim Batzoglou | Seer Inc | N/A | |
| Johannes Houte | Nurix Therapeutics | 58 | |
| MD MPH | MediciNova | 56 | |
| Claudia Drayton | QuantumSi | 56 | |
| Pr MD | Nurix Therapeutics | N/A | |
| JD Esq | Nurix Therapeutics | 63 | |
| Gwenn Hansen | Nurix Therapeutics | 53 | |
| Peter Rhode | HCW Biologics | 66 | |
| Prof Shair | Nuvalent | 55 | |
| Marissa Dixon | Seer Inc | N/A | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.14 |
Oxford Nanopore Tech Leadership Team
Elected by the shareholders, the Oxford Nanopore's board of directors comprises two types of representatives: Oxford Nanopore inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oxford. The board's role is to monitor Oxford Nanopore's management team and ensure that shareholders' interests are well served. Oxford Nanopore's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oxford Nanopore's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tim Cowper, CFO Director | ||
| Sara Le, VP Marketing | ||
| Sarah Lapworth, VP HR | ||
| Jordan Herman, Sr Counsel | ||
| Richard Compton, VP Operations | ||
| John Schoellerman, Sr Relations | ||
| Pr Bayley, CoFounder Board | ||
| Rhodri Davies, VP Operations | ||
| Gordon Sanghera, CEO CoFounder | ||
| Clive Brown, CTO Director |
Oxford Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oxford Nanopore a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.78) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 1.7 B | |||
| Shares Outstanding | 825.96 M | |||
| Shares Owned By Insiders | 34.06 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Book | 2.69 X | |||
| Price To Sales | 12.58 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Oxford Pink Sheet
Oxford Nanopore financial ratios help investors to determine whether Oxford Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oxford with respect to the benefits of owning Oxford Nanopore security.